BEIJING, March 25, 2011 /PRNewswire-Asia/ — Sinovac Biotech
Ltd. (Nasdaq:
SVA), a leading provider of biopharmaceutical products in
China, announced today that Dr. Weidong Yin, President and CEO, and
Ms. Helen Yang, Investor Relations Manager, are scheduled to
participate in the UBS Greater China Healthcare Corporate Day.
The conference will be held in Hong Kong at UBS Office from
March 28th to March 29. The Sinovac team will present and
participate in small group and one-on-one meetings on March
28th.
About SinovacSinovac Biotech Ltd. is a China-based
biopharmaceutical company that focuses on the research,
development, manufacture and commercialization of vaccines that
protect against human infectious diseases including hepatitis A,
seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1
influenza. In 2009, Sinovac was the first company worldwide to
receive approval for its H1N1 influenza vaccine, PANFLU.1, and has
received orders from the Chinese Central Government pursuit to the
government stockpiling program. The Company is developing a number
of new vaccine products, including vaccines for pneumococcal
conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth
Disease), Japanese Encephalitis, animal and human rabies, HIB and
epidemic meningitis, chickenpox, mumps and rubella. Its wholly
owned subsidiary, Tangshan Yian, is focusing on the research,
development, manufacturing and commercialization of animal vaccines
and has completed the field trials for an independently developed
inactivated animal rabies vaccine, which is anticipated to be
launched into market in 2011.
Safe Harbor StatementThis announcement contains
forward-looking statements. These statements are made under the
“safe harbor” provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by words or phrase
‘/>”/>
